Health TrialsbyHealthPanel

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults

ConditionChronic Liver Disease (CLD)
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age19-64
SponsorAddpharma Inc.

About this trial

A Clinical Trial to Evaluate the Pharmacokinetics and Safety of AD-230 in Healthy Adults

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

- Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening visit

Subjects aged 19 years or older and under 65 years at the screening visit

Disqualifiers

Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration

Other exclusions applied

Trial design

Design model

Crossover

Treatments tested in this trial

  • AD-230, AD-2301

    Drug

    Oral administration of AD-230 or AD-2301, according to randomized sequence.

Treatment groups

52 Participants
are divided into 2 treatment groups
Group A: Sequence AExperimental treatment 1 intervention
Group B: Sequence BExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

AUClast

Time frame
-24hours to 72hours
2

Cmax

Time frame
-24hours to 72hours

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Addpharma Inc.

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: